Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

Early Data for OMX-0407 Fuel Expansion Cohorts in RCC, Angiosarcoma

August 27th 2024

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

FDA Grants Priority Review to Vimseltinib in Tenosynovial Giant Cell Tumor

August 16th 2024

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Dr Randall on the Role of EZH2 in Doxorubicin Resistance in Soft Tissue Sarcoma

August 15th 2024

R. Lor Randall, MD, FACS, discusses the role of EZH2 in doxorubicin resistance in soft tissue sarcoma.

Research Across 5 Sarcoma Stem Cell Subtypes Identifies EZH2 as a Potential Therapeutic Target

August 9th 2024

R. Lor Randall, MD, FACS, details findings from a genetic and epigenetic study showing 5 sarcoma subtypes had EZH2 activity and a shared epigenetic profile.

FDA Clears Companion Diagnostic for Afami-Cel in Pretreated Metastatic Synovial Sarcoma

August 6th 2024

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

FDA Grants Accelerated Approval to Afami-Cel for Advanced Synovial Sarcoma

August 2nd 2024

The FDA has granted accelerated approval to afamitresgene autoleucel for select patients with pretreated unresectable or metastatic synovial sarcoma.

Proactive Measures and a Multidisciplinary Approach Are Key for Diagnosis and Management of Sarcoma

July 31st 2024

Adam C. Berger, MD, FACS, discusses key messages for oncologists during Sarcoma Awareness Month.

Sarcoma Awareness Month 2024: Recognizing Symptoms, Scanning Patients Key to Diagnosis

July 30th 2024

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

EU Approval Sought for Vimseltinib in Tenosynovial Giant Cell Tumor

July 19th 2024

The marketing authorization application seeking the approval of vimseltinib for the treatment of tenosynovial giant cell tumor is under EMA review.

Dr Kelly on the Role of Ripretinib in the GIST Treatment Paradigm

July 16th 2024

Ciara Kelly, MBBCh, BAO, discusses the current and potential roles for ripretinib in the gastrointestinal stromal tumor treatment paradigm.

Dr Agulnik on the Evolving Management of Heterogenous Disease in GIST

July 16th 2024

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

Innovative Research Continues to Propel Individualized GIST Treatments

July 13th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.

Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma

July 7th 2024

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

June 7th 2024

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma

May 14th 2024

R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

May 10th 2024

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.

Eftilagimod Alpha–Based Triplet Is Well Tolerated, Generates Responses in Soft Tissue Sarcoma

May 2nd 2024

Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.